Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02859428 · ClinicalTrials.gov registry record
Disease Natural History and Biomarkers of SPG3A, SPG4A, and SPG31
A clinical trial, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).
- Terminated
- Registry status
- 51
- Enrollment target
NCT02859428 is a clinical trial that was terminated before completion, run by National Institute of Neurological Disorders and Stroke (NINDS). The registered enrollment target is 51 participants.
The verdict
NCT02859428 was terminated before completion, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).
- TERMINATED
- Registry status
- 51 participants
- Enrollment target
Study Summary
Background: Hereditary spastic paraplegia (HSP) usually progresses slowly. Researchers want to learn more about how its symptoms change over time. They want to look for changes in the blood and cells of people with the most common forms of HSP that might allow them to better understand the disease. Objectives: To learn more about common forms of hereditary spastic paraplegia and find out how it progresses over time. Eligibility: People age 7 and older with SPG3A, SPG4A, or SPG31 Design: Participants will have 1 two-hour visit each year for up to 5 years. At 1 visit, adult participants may have a skin biopsy. An area of skin will be numbed then a tool will remove a small piece of skin. At all visits, all participants will have a physical exam and blood drawn. At all visits, participants will do a few tasks like walking quickly and climbing stairs. Participants can give permission for their skin cells, DNA samples, and data to be used in other studies. The samples and data will have no identifying information.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2016-11-18 |
| Est. Completion | 2020-10-16 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02859428
The ClinicalTrials.gov registry entry for NCT02859428 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Neurological Disorders and Stroke (NINDS), which has 567 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02859428 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02859428 about?
NCT02859428 is a clinical study titled "Disease Natural History and Biomarkers of SPG3A, SPG4A, and SPG31". Background: Hereditary spastic paraplegia (HSP) usually progresses slowly. Researchers want to learn more about how its symptoms change over time. They want to look for changes in the blood and cells of people with the most common forms of HSP that might allow them to better understand the disease....
What is the current status of trial NCT02859428?
This trial is currently terminated. The enrollment target is 51 participants. The study started on 2016-11-18. Estimated completion is 2020-10-16.
Who is sponsoring clinical trial NCT02859428?
This trial is sponsored by National Institute of Neurological Disorders and Stroke (NINDS), which has 567 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.